Overview

A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia

Status:
Terminated
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This pilot study will assess the safety and efficacy of Pivanex alone in patients with chronic lymphocytic leukemia (CLL) who have relapsed or refractory disease after previous chemotherapy treatment. Pivanex is an investigational agent.
Phase:
Phase 2
Details
Lead Sponsor:
Titan Pharmaceuticals
Treatments:
Histone Deacetylase Inhibitors